Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Free Cash Flow (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Free Cash Flow data on record, last reported at -$28.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 52.58% year-over-year to -$28.0 million; the TTM value through Dec 2025 reached -$123.5 million, up 26.41%, while the annual FY2025 figure was -$123.5 million, 26.41% up from the prior year.
  • Free Cash Flow reached -$28.0 million in Q4 2025 per AMLX's latest filing, up from -$30.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $13.2 million in Q4 2023 and bottomed at -$66.7 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$26.9 million, with a median of -$28.2 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: soared 126.22% in 2023, then tumbled 7064.57% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$28.4 million in 2021, then plummeted by 76.99% to -$50.3 million in 2022, then skyrocketed by 126.22% to $13.2 million in 2023, then plummeted by 547.35% to -$59.0 million in 2024, then skyrocketed by 52.58% to -$28.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$28.0 million in Q4 2025, -$30.4 million in Q3 2025, and -$25.3 million in Q2 2025.